Indivior PLC (LON:INDV)

London flag London · Delayed Price · Currency is GBP · Price in GBX
783.00
+11.00 (1.42%)
Apr 25, 2025, 8:37 AM BST
-48.49%
Market Cap 963.14M
Revenue (ttm) 905.57M
Net Income (ttm) -47.99M
Shares Out 124.76M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE 8.19
Dividend n/a
Ex-Dividend Date n/a
Volume 20,380
Average Volume 310,259
Open 786.00
Previous Close 772.00
Day's Range 782.50 - 799.50
52-Week Range 548.71 - 1,485.00
Beta 0.32
RSI 59.11
Earnings Date Apr 25, 2025

About Indivior

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally. The company develops medicines to treat substance use disorders. Its core marketed products include SUBLOCADE buprenorphine extended-release monthly injections; SUBOXONE Film, a buprenorphine and naloxone sublingual film; SUBOXONE Tablet, a buprenorphine and naloxone sublingual tablet; and SUBUTEX T... [Read more]

Sector Healthcare
Founded 2014
Employees 1,051
Stock Exchange London Stock Exchange
Ticker Symbol INDV
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

A Look at Indivior's Upcoming Earnings Report

Indivior (NASDAQ: INDV) is set to give its latest quarterly earnings report on Thursday, 2025-04-24. Here's what investors need to know before the announcement. Analysts estimate that Indivior will r...

1 day ago - Benzinga

Decoding Indivior PLC (INDV): A Strategic SWOT Insight

Decoding Indivior PLC (INDV): A Strategic SWOT Insight

7 weeks ago - GuruFocus

Two Seas Capital LP Reduces Stake in Indivior PLC

Two Seas Capital LP Reduces Stake in Indivior PLC

7 weeks ago - GuruFocus

Indivior Announces Further Changes to Board of Directors

RICHMOND, Va. , March 4, 2025 /PRNewswire/ -- Indivior PLC (NASDAQ / LSE: INDV) ("Indivior" or the "Company") today announced that, further to the announcement on December 17, 2024 of certain Director...

7 weeks ago - PRNewsWire

UK's Indivior appoints Joe Ciaffoni as CEO

British drugmaker Indivior on Thursday said it appointed Joe Ciaffoni as its new CEO, replacing current boss Mark Crossley.

2 months ago - Reuters

Indivior Announces Joseph Ciaffoni Appointed Chief Executive Officer

RICHMOND, Va. , Feb. 27, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer.

2 months ago - PRNewsWire

Indivior Announces FDA Approval of Label Changes for SUBLOCADE® (buprenorphine extended-release) Injection

Rapid Initiation Protocol Reduces Time to Treatment with SUBLOCADE ® From One Week to One Hour, A Significant Advancement in the Treatment of Moderate to Severe Opioid Use Disorder (OUD) RICHMOND, Va....

2 months ago - PRNewsWire

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Indivior Plc (NASDAQ: INDV) stock plunged following the company’s fiscal year 2025 guidance that fell short of Street expectations. Addiction and mental illnesses-focused Indivior reported fourth-qua...

2 months ago - Benzinga

European Addiction-Focused Indivior Stock Falls As Drugmaker Warns Lower Revenues In 2025 Despite Q4 Earnings Beat

Indivior Plc INDV stock plunged following the company's fiscal year 2025 guidance that fell short of Street expectations.

2 months ago - Benzinga

Earnings To Watch: Indivior PLC (INDV) Reports Q4 2024 Result

Earnings To Watch: Indivior PLC (INDV) Reports Q4 2024 Result

2 months ago - GuruFocus

UK's Indivior forecasts 17% decline in 2025 revenue

British drugmaker Indivior on Thursday projected a 17% decline in 2025 net revenue at the midpoint of its forecast range, partly hurt by sluggish sales of its film-form medication-assisted therapy for...

2 months ago - Reuters

Indivior reports Q4 results

2 months ago - Seeking Alpha

Indivior Announces FY and Q4 2024 Financial Results

SLOUGH, United Kingdom and RICHMOND, Va. , Feb. 20, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) today announced its financial results for the period ending December 31, 2024.

2 months ago - PRNewsWire

Indivior PLC (INDV) Shares Down 0.83% on Feb 19

Indivior PLC (INDV) Shares Down 0.83% on Feb 19

2 months ago - GuruFocus

Indivior Statement RE: Delayed FDA Approval of SUBLOCADE® Label Changes

RICHMOND, Va. , Feb. 12, 2025 /PRNewswire/ -- Indivior PLC (Nasdaq/LSE: INDV) provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative...

2 months ago - PRNewsWire

Two Seas Capital LP Adjusts Position in Indivior PLC

Two Seas Capital LP Adjusts Position in Indivior PLC

3 months ago - GuruFocus

Indivior CFO steps down from board after discussions with Oaktree Capital

Indivior (INDV) stock in focus as CFO resigns from board amid pressure from Oaktree Capital Management. Read more here.

4 months ago - Seeking Alpha

BUSINESS LIVE: Wage growth accelerates; Britvic takeover cleared; Capita to cut more staff

Among the companies with reports and trading updates today are Britvic, Capita, Chemring and Indivior.

4 months ago - This is Money

Indivior PLC (INDV) Trading 3.1% Higher on Nov 19

Indivior PLC (INDV) Trading 3.1% Higher on Nov 19

5 months ago - GuruFocus

Rapid Initiation with Once-monthly SUBLOCADE® Superior to Standard Initiation for Treating Opioid Use Disorder, Including in Fentanyl-Positive Patients, According to Data Presented at CSAM 2024

Data show rapid initiation with once-monthly SUBLOCADE significantly improves retention in opioid use disorder (OUD) patients, especially among fentanyl-positive participants. Study also administered ...

5 months ago - PRNewsWire

SCOPIA CAPITAL MANAGEMENT LP Adjusts Stake in Indivior PLC

SCOPIA CAPITAL MANAGEMENT LP Adjusts Stake in Indivior PLC

5 months ago - GuruFocus